Editorial Commentary: Should "heterogeneous response" be considered as new category for assessing treatment response in patients with breast cancer?

Affiliations

• ¹ Nuclear Medicine- Radiopharmacology, Champalimaud Clinical Center, Champalimaud Foundation, Lisbon, Portugal.
• ² Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands.
• ³ Nuclear Medicine Department, Saint- Louis Hospital, Paris, France.
• ⁴ University Paris-Diderot, INSERM U976, Paris, France.
• ⁵ Centre d'Imagerie Radio-Isotopique (CIRI), La Rochelle, France.
• ⁶ Department of Radiology and Nuclear Medicine, Maastricht University Medical Center+, Maastricht, the Netherlands.
• ⁷ NUTRIM, Maastricht University Medical Center+, Maastricht, the Netherlands.
• ⁸ Department of Nuclear Medicine, Ospedale San Raffaele, Milan, Italy.
• ⁹ Breast Unit, Champalimaud Clinical Center, Champalimaud Foundation, Lisbon, Portugal.
• ¹⁰ Advanced Breast Cancer Global Alliance, Lisbon, Portugal.
• ¹¹ Department of Nuclear Medicine, University Hospital, RWTH Aachen University, Aachen, Germany.
• ¹² GROW- Research institute for Oncology and Reproduction, Maastricht University Medical Center+, Maastricht, the Netherlands.
• ¹³ NOVA medical school, Lisbon, Portugal.
• ¹⁴ ImagingWest, Hawthorne, NY, USA.
• ¹⁵ Biomedical Photonic Imaging Group, University of Twente, Enschede, The Netherlands.
• ¹⁶ Department of radiation Science & Technology, Technical University of Delft, Delft, The Netherlands.
• ¹⁷ Molecular Imaging and Therapy, Hoag Family Cancer Institute, Newport Beach, CA, USA. [email protected].
• ¹⁸ University of Southern California, Los Angeles, CA, USA. [email protected].